Literature DB >> 10511594

Growth regulation of prostatic stromal cells by prostate-specific antigen.

D M Sutkowski1, R L Goode, J Baniel, C Teater, P Cohen, A M McNulty, H M Hsiung, G W Becker, B L Neubauer.   

Abstract

BACKGROUND: Prostate-specific antigen (PSA) is a serine protease that can cleave insulin-like growth factor-binding protein-3 (IGFBP3), thereby decreasing its affinity for insulin-like growth factor-I (IGF-I). Dissociation of the IGF-I-IGFBP3 complex renders IGF-I available to bind to its receptor and stimulates cellular proliferation. We evaluated the potential for PSA to modulate the effects of IGF-I and IGFBP3 on the proliferation of human benign prostatic hyperplasia (BPH)-derived fibromuscular stromal cells in primary cultures.
METHODS: We cultured BPH-derived stromal cells for 48 hours in serum-free RPMI-1640 medium supplemented with 0.2% bovine serum albumin and studied the effects of IGF-I, IGFBP3, PSA, and ZnCl(2) at varying concentrations. Differences in cell growth between control and treated cultures were evaluated by use of Dunnett's test. Concentration-related trends were evaluated by linear regression of log-transformed concentrations of test reagents on BPH-derived stromal cell number responses. Statistical tests were two-sided.
RESULTS: We observed a concentration-dependent proliferative response of BPH-derived stromal cells to IGF-I. IGFBP3 inhibited this response in a concentration-dependent fashion. IGFBP3 alone had no effect on stromal cell proliferation. When stromal cells were incubated with PSA alone or with PSA, IGF-I, and IGFBP3, an increase in stromal cell numbers that was dependent on PSA concentration was evident in both instances. Zinc, an endogenous inhibitor of PSA enzymatic activity, was able to attenuate the stimulatory effect of PSA at intraprostatic physiologic concentrations.
CONCLUSIONS: These results are consistent with the idea that PSA can modulate in vitro interactions between IGF-I and IGFBP3 and suggest that PSA may play a role in the regulation of human prostatic fibromuscular cell growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511594     DOI: 10.1093/jnci/91.19.1663

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  11 in total

1.  Proteomic analysis of patient tissue reveals PSA protein in the stroma of benign prostatic hyperplasia.

Authors:  Katherine J O'Malley; Kurtis Eisermann; Laura E Pascal; Anil V Parwani; Tsuyoshi Majima; Lara Graham; Katherine Hrebinko; Marie Acquafondata; Nicolas A Stewart; Joel B Nelson; Naoki Yoshimura; Zhou Wang
Journal:  Prostate       Date:  2014-04-07       Impact factor: 4.104

2.  E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer.

Authors:  Feng Li; Laura E Pascal; Donna B Stolz; Ke Wang; Yibin Zhou; Wei Chen; Yadong Xu; Yule Chen; Rajiv Dhir; Anil V Parwani; Joel B Nelson; Donald B DeFranco; Naoki Yoshimura; Goundappa K Balasubramani; Jeffrey R Gingrich; Jodi K Maranchie; Bruce L Jacobs; Benjamin J Davies; Ronald L Hrebinko; Joel D Bigley; Dawn McBride; Peng Guo; Dalin He; Zhou Wang
Journal:  Prostate       Date:  2019-06-18       Impact factor: 4.104

3.  Evidence for the novel expression of human kallikrein-related peptidase 3, prostate-specific antigen, in the brain.

Authors:  Jeremy G Stone; Raj K Rolston; Masumi Ueda; Hyoung-Gon Lee; Sandy L Richardson; Rudy J Castellani; George Perry; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-10-20

4.  "Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response.

Authors:  Adaikkalam Vellaichamy; Zoltán Dezso; Lellean JeBailey; Arul M Chinnaiyan; Arun Sreekumar; Alexey I Nesvizhskii; Gilbert S Omenn; Andrej Bugrim
Journal:  PLoS One       Date:  2010-06-03       Impact factor: 3.240

5.  Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation.

Authors:  Yuanjie Niu; Shuyuan Yeh; Hiroshi Miyamoto; Gonghui Li; Saleh Altuwaijri; Jianqun Yuan; Ruifa Han; Tengxiang Ma; Hann-Chorng Kuo; Chawnshang Chang
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

6.  Ovarian cancer, the coagulation pathway, and inflammation.

Authors:  Xipeng Wang; Ena Wang; John J Kavanagh; Ralph S Freedman
Journal:  J Transl Med       Date:  2005-06-21       Impact factor: 5.531

7.  Down regulation of PSA by C/EBPalpha is associated with loss of AR expression and inhibition of PSA promoter activity in the LNCaP cell line.

Authors:  Hong Yin; Hanna S Radomska; Daniel G Tenen; Jonathan Glass
Journal:  BMC Cancer       Date:  2006-06-14       Impact factor: 4.430

Review 8.  Remodelling of the tumour microenvironment by the kallikrein-related peptidases.

Authors:  Srilakshmi Srinivasan; Thomas Kryza; Jyotsna Batra; Judith Clements
Journal:  Nat Rev Cancer       Date:  2022-01-31       Impact factor: 69.800

9.  Prediction of prostate cancer recurrence using quantitative phase imaging.

Authors:  Shamira Sridharan; Virgilia Macias; Krishnarao Tangella; André Kajdacsy-Balla; Gabriel Popescu
Journal:  Sci Rep       Date:  2015-05-15       Impact factor: 4.379

10.  A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer.

Authors:  Sang Wook Lee; Kazuo Hosokawa; Soyoun Kim; Ok Chan Jeong; Hans Lilja; Thomas Laurell; Mizuo Maeda
Journal:  Sensors (Basel)       Date:  2015-05-22       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.